Certara (NASDAQ:CERT) provides software and technology-enabled services that support the development, approval and commercialization of medicines. The company specializes in model-informed drug development, using pharmacometrics, simulation, data analysis and regulatory science to help biopharmaceutical companies evaluate drug safety, efficacy, dosing and potential regulatory outcomes.
Its software portfolio includes platforms such as Simcyp, which supports clinical pharmacology and drug-interaction modeling; Phoenix, used for pharmacokinetic and pharmacodynamic analysis; and Pinnacle 21, which helps organizations manage clinical data standards and regulatory submissions. Certara also provides consulting and related services covering clinical pharmacology, regulatory strategy, quantitative systems pharmacology, real-world evidence, biostatistics and market access.
Certara serves pharmaceutical, biotechnology and academic organizations, as well as regulatory agencies, across global markets. The company was formed through the combination of businesses focused on pharmacometric software and consulting and became a publicly traded company in 2020. Its offerings are designed to help customers make development decisions, address regulatory requirements and potentially improve the efficiency of the drug-development process.
AI Generated. May Contain Errors.
